These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 19776379

  • 1. Ocular toxoplasmosis during natalizumab treatment.
    Zecca C, Nessi F, Bernasconi E, Gobbi C.
    Neurology; 2009 Oct 27; 73(17):1418-9. PubMed ID: 19776379
    [No Abstract] [Full Text] [Related]

  • 2. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
    Stüve O, Wiendl H.
    Neurology; 2009 Oct 27; 73(17):1346-7. PubMed ID: 19776376
    [No Abstract] [Full Text] [Related]

  • 3. Natalizumab for relapsing multiple sclerosis.
    Meyer MA.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract] [Full Text] [Related]

  • 4. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 5. [New drugs; natalizumab].
    van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Mar 01; 152(9):499-500. PubMed ID: 18389881
    [Abstract] [Full Text] [Related]

  • 6. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?
    Bergamaschi R, Montomoli C.
    Mult Scler; 2009 Dec 01; 15(12):1532-3. PubMed ID: 20019096
    [Abstract] [Full Text] [Related]

  • 7. Quantitative risk-benefit analysis of natalizumab.
    Steiner I.
    Neurology; 2009 May 19; 72(20):1791-2; author reply 1791-2. PubMed ID: 19451538
    [No Abstract] [Full Text] [Related]

  • 8. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    De Gascun CF, Lonergan RM, Hall WW.
    N Engl J Med; 2009 Dec 17; 361(25):2488-9; author reply 2489-90. PubMed ID: 20050215
    [No Abstract] [Full Text] [Related]

  • 9. Natalizumab for relapsing multiple sclerosis.
    Chaudhuri A, Behan PO.
    N Engl J Med; 2003 Apr 17; 348(16):1598-9; author reply 1598-9. PubMed ID: 12700382
    [No Abstract] [Full Text] [Related]

  • 10. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep 11; 48(1243):76. PubMed ID: 16977289
    [No Abstract] [Full Text] [Related]

  • 11. Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies.
    Killestein J, Jasperse B, Liedorp M, Seewann A, Polman Ch.
    Mult Scler; 2009 Apr 11; 15(4):525-6. PubMed ID: 19324985
    [No Abstract] [Full Text] [Related]

  • 12. An approach to natalizumab hypersensitivity: a case series of induction of tolerance.
    Camacho-Halili M, George R, Gottesman M, Davis-Lorton M.
    Mult Scler; 2011 Feb 11; 17(2):250-3. PubMed ID: 21177321
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM.
    N Engl J Med; 2008 Jun 12; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract] [Full Text] [Related]

  • 14. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Gorelik L, Goelz S, Sandrock AW.
    N Engl J Med; 2009 Dec 17; 361(25):2487-8; author reply 2489-90. PubMed ID: 20018972
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
    Naismith RT, Bourdette D.
    Neurology; 2011 May 31; 76(22):1854-5. PubMed ID: 21543735
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Natalizumab effects on immune cell responses in multiple sclerosis.
    Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A.
    Ann Neurol; 2006 May 31; 59(5):748-54. PubMed ID: 16634035
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes.
    Stüve O, Cravens PD, Singh MP, Frohman EM, Phillips JT, Remington G, Hu W, Hemmer B, Olek MJ, Monson NL, Racke MK.
    Arch Neurol; 2007 Jul 31; 64(7):1055-6. PubMed ID: 17620501
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.